|
12 Feb 2021 |
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
|
|
12 Feb 2021 |
Takeda’s Maribavir P3 Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy for Cytomegalovirus
|
|
12 Feb 2021 |
Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium
|
|
12 Feb 2021 |
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
|
|
12 Feb 2021 |
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
|
|
12 Feb 2021 |
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
|
|
12 Feb 2021 |
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
|
|
12 Feb 2021 |
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
|
|
11 Feb 2021 |
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
|
|
11 Feb 2021 |
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
|
|
11 Feb 2021 |
Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform
|
|
11 Feb 2021 |
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
|
11 Feb 2021 |
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
|
|
10 Feb 2021 |
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
|
|
10 Feb 2021 |
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
|
|
10 Feb 2021 |
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections
|
|
10 Feb 2021 |
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
|
|
10 Feb 2021 |
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
|
|
10 Feb 2021 |
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
|
|
10 Feb 2021 |
AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
|
